Table 2: Solid tumor responses comparisons of HCC patients.

ComparisonsStudiesGroupsClinical responses (%) HeterogeneityRR95% CIP value
Chi2dfP (%)

Complete response (CR)[22, 23, 29, 30, 32, 3436]Treatment44/442 (10.0)3.0770.8801.470.96–2.240.07
Control26/406 (6.4)
Partial response (PR)[20, 2225, 27, 29, 30, 32, 3436, 38]Treatment210/610 (34.4)9.96120.6201.301.10–1.530.002
Control145/551 (26.3)
Stable disease (SD)[20, 2225, 27, 29, 30, 32, 3436, 38]Treatment260/610 (42.6)15.89120.2240.950.84–1.080.47
Control241/551 (43.7)
Progressive disease (PD)[20, 2225, 27, 29, 30, 32, 3436, 38]Treatment101/610 (16.6)9.22120.6800.640.52–0.800.0001
Control146/551 (26.5)
Total response rate (tRR)[20, 2225, 27, 29, 30, 32, 3436, 38]Treatment254/610 (41.6)13.56120.33121.31.16–1.530.0001
Control171/551 (31.0)